Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience

Danai Dimaa Hematology/Oncology Division, Cleveland Clinic Foundation, Cleveland, OH, USACorrespondence[email protected]

https://orcid.org/0000-0002-3587-7975 View further author information

Xiao Hub Hematology/Oncology Division, Tufts Medical Center, Boston, MA, USA

https://orcid.org/0000-0001-9036-8455 View further author information

Joshua Dowerb Hematology/Oncology Division, Tufts Medical Center, Boston, MA, USAView further author information

Diana Zhangc Internal Medicine Division, Massachusetts General Hospital, Boston, MA, USAView further author information

Raymond Comenzod The John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USAView further author information

Cindy Vargad The John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USAView further author information

Click to increase image sizeClick to decrease image size

Disclosure statement

Dr. Raymond Comenzo: Sanofi-consultancy, Janssen-Patents & Royalties, Janssen, Caelum, Alnylam-Research Funding. The rest of the authors declare no potential conflict of interest.

Additional information

Funding

This present work received no funding from agencies in the public, commercial or non-for-profit sectors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience

Information for

Open access

Opportunities

Help and information

Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature